The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.
about
Effect of Anti-TNF Antibodies on Clinical Response in Rheumatoid Arthritis Patients: A Meta-AnalysisBiologic efficacy optimization--a step towards personalized medicineImmunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practiceBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisClassical and recent advances in the treatment of inflammatory bowel diseasesJakpot! New small molecules in autoimmune and inflammatory diseasesPredictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.Antidrug Antibodies: B Cell Immunity Against TherapyAnti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort StudyInfluence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional studyEvaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis.Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuationInfluence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients.Protective effects of tumor necrosis factor-α blockade by adalimumab on articular cartilage and subchondral bone in a rat model of osteoarthritisDevelopment of a Recombinant Xenogeneic Tumor Necrosis Factor Alpha Protein Vaccine To Protect Mice from Experimental Colitis.Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.Evaluating and Reporting the Immunogenicity Impacts for Biological Products--a Clinical Pharmacology PerspectiveCost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockersClinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels.A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practiceAnti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence.High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort.Golimumab pharmacokinetics in ulcerative colitis: a literature reviewThe role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.Antidrug antibodies in psoriasis: a systematic review.Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis.Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review.Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis.The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences.Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions.Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies.Strategies for reducing inhibitor formation in severe haemophilia.Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review.Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate.
P2860
Q26739150-229D9BB9-AA97-42B7-8F58-4ED907551AFFQ26783657-C860C4F6-146A-42C2-80DD-CCB945A7A688Q26798357-EE587810-0529-4856-AD7D-AE7A2B23DBEFQ26852235-AAD34F09-DB2C-47C7-B50C-CF9FE159558AQ26861725-717220C8-8185-4752-AFF2-091F70395D18Q27001957-50E246BA-CF2F-41C7-943E-E369D27C1231Q27692641-F0118F31-F3FB-452E-8A51-46F8A73361BEQ28082303-C150F57B-6596-4E86-AD54-C06456688D9EQ28553954-340A4682-CEC3-44C4-95C5-20E395C50D69Q30240229-787521BE-2435-4B00-B7CF-7F42EF5DD7A0Q30940329-02C9B1AA-8CA7-4AAE-9F97-6CB8F3758145Q30995889-4A834AF5-1474-44FE-A62B-4683E2F77708Q33610284-B9AA0144-7EEF-42DB-A2B3-78F2935958B1Q33726030-3EC63E07-EDD7-4165-A6E2-3136D9D8756CQ33932779-1F2FA45C-55DC-4A09-828B-7EF842631A6DQ34208252-125209AF-5659-49BC-9988-3033038DC611Q34669637-A463D992-AE44-4BEF-B0E8-AD895B8AA28AQ35592110-A55A7E05-74F6-459A-A814-5617B5A7044CQ36196730-3E3A3C62-A144-46C5-B952-A4124EC2E674Q36316797-AADE29FD-BC7F-496C-99EA-60CA4EC9D2DAQ36347059-F51F16D8-F83F-4F60-AD93-8B018F11793BQ36653930-69E05B81-8448-4D83-BA6D-6C0717B06D55Q36776326-A37116F2-3F53-4B70-914A-70BEA443D5A6Q36832755-0EC2E143-9CF2-4AC7-8096-0119EC0750A5Q37383419-8463C992-F858-4FCE-B918-E5A87B3E5E9AQ37484873-A14B1321-2F90-4FEC-A42A-9B08D88C4535Q37517101-2C99F722-14C6-4FD6-AB10-7C6E29DB7186Q37604498-BF1ED35E-8088-4EA5-8E16-013B8BE1F909Q37671983-43296F77-6DA3-40A1-968C-2EE8714745B8Q38129037-01A58689-A931-4AA6-AA93-BD216BB7C58EQ38151757-B1871851-BE6E-46E0-94D5-CF566847852CQ38198090-BDCE27AD-993E-4558-B7C6-7D6DE0AD067DQ38201788-8D0A50E8-BAB3-4158-8D8A-594E73F7EA59Q38203622-DB308FDD-1446-4424-8992-669840C35D48Q38222900-436D1A9D-EE0F-4516-897B-1D08C856BB26Q38286010-53ADFCEB-0EA1-46F6-98F3-62946F58C085Q38306139-DBD202CA-805F-43FC-8B23-AF362EA60E95Q38308222-DE27A051-E301-4C4E-BEC3-ACB1E2F5AE10Q38338700-B94B0396-FCF4-4924-A04C-B16CB70B1E7BQ38473460-69237B7D-782D-48D2-8686-C50F7C38258F
P2860
The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The immunogenicity of anti-TNF ...... terature with a meta-analysis.
@en
type
label
The immunogenicity of anti-TNF ...... terature with a meta-analysis.
@en
prefLabel
The immunogenicity of anti-TNF ...... terature with a meta-analysis.
@en
P31
P921
P1476
The immunogenicity of anti-TNF ...... terature with a meta-analysis.
@en
P2093
Elizabeth Benito-Garcia
P304
P356
10.1136/ANNRHEUMDIS-2012-202220
P407
P577
2012-12-06T00:00:00Z